Icecure Medical Ltd

IceCure Medical Ltd. is a commercial stage medical device company. It is engaged in the research, development, and marketing of cryoablation systems, disposables, and technologies based on liquid nitrogen for treating tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Icecure Medical reports revenue growth and regulatory milestones in Q1

Icecure Medical Ltd (ICCM) demonstrated strong revenue growth and regulatory progress in Q1 2024, despite a net loss, reflecting a resilient business outlook.
The company's focus on product development, market acceptance, and strategic planning underscores a commitment to long-term success and sustainability.
Addressing cost management, optimizing pricing strategies, and seizing market opportunities will be crucial for Icecure to enhance profitability and drive growth.

Icecure Medical reports robust Q2 sales growth and FDA progress

Icecure Medical's Q2 2024 performance showcased strong sales growth and improved financial metrics.
While facing challenges such as regulatory processes and leadership continuity, the company's strengths lie in its product acceptance and fundraising success.
Opportunities in FDA approvals and market expansion present avenues for future growth and profitability for Icecure Medical.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Latest system installation in IceCure's global commercial rollout of ProSense CAESAREA, Israel , May 31, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that ProSense was recently installed and inaugurated at Kovai Medical Center and Hospital ("KMCH") in Coimbatore, India.

IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country

IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2023 Earnings Conference Call May 22, 2023 10:00 AM ET Company Participants Todd Kehrli - EVC Group, IR Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - Vice President, Business Development and Global Marketing Ronen Tsimerman - Chief Financial Officer and COO Conference Call Participants Chait G - H.C. Wainwright Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning and thank you for standing by.

IceCure Medical Ltd (ICCM) Q1 2023 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09.

IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates

Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the only Cryoablation System Used in a First-of-its-Kind Cryotherapy Continuing Medical Education (CME) course at the American Society of Breast Surgeons (ASBrS) 2023 Annual Meeting Where a Plan was Presented for a Proposed ASBrS Cryoablation Trial Regulatory Approval Received in China for Commercial Use of Disposable Cryoprobes Independently Conducted Endometriosis Study Shows 92.8% Efficacy in Avoiding Secondary Surgery Conference Call to be Held Today at 10:00 am Eastern Time CAESAREA, Israel , May 22, 2023 /PRNewswire/-- IceCure Medical Ltd. (the "Company" or "IceCure") (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.

IceCure Medical Reports First Quarter 2023 Financial & Operational Results

CAESAREA, Israel, May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday, May 22, 2023 and will host a conference call at 10:00 a.m.

IceCure to Report First Quarter 2023 Financial & Operational Results on May 22, 2023

CAESAREA, Israel , May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday, May 22, 2023 and will host a conference call at 10:00 a.m.

IceCure to Report First Quarter 2023 Financial & Operational Results on

IceCure's ProSense was the cryoablation system used in first-of-its-kind cryotherapy continuing medical education (CME) course High level of interest expressed in cryoablation from attending surgeons and from American Society of Breast Surgeons (ASBrS) leadership Plan presented for a proposed ASBrS Cryoablation trial during CME course CAESAREA, Israel , May 1, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its participation in the American Society of Breast Surgeons' (ASBrS) 24th Annual Meeting, which took place in Boston on April 26-30, 2023, resulted in high levels of interest in ProSense.

Cryoablation Takes Center Stage at American Society of Breast Surgeons' 24th Annual Meeting

Physicians Attending the CME Course to Demo ProSense, Learn More About Breast Cryoablation, and Receive Hands-on Training Previously Published ICE3 Trial Interim Results will be Highlighted to Further Raise Awareness of Breast Cryoablation CAESAREA, Israel , April 24, 2023 IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its educational support for a continuing medical education (CME) course on cryotherapy at the American Society of Breast Surgeons' (ASBrS) 24th Annual Meeting to be held in Boston, Massachusetts on April 26-30, 2023.

IceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons' 24th Annual Meeting

ProSense System among the two types of systems used in the study Pain-free survival rates of 93.75% at 6 months and 82.72% at 36 months post-procedure 190 million women globally live with endometriosis, for which there is no cure; current treatments aim to control symptoms Data presented at Society of Interventional Radiology 2023 Annual Scientific Meeting by lead investigator Francois H. Cornelis, MD, PhD CAESAREA, Israel , April 20, 2023 /PRNewswire/ -- IceCure Medical Ltd.

IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery

CAESAREA, Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announces that it has initiated a process to voluntarily delist its ordinary shares, no par value per share (the "Ordinary Shares"), from the Tel Aviv Stock Exchange (the "TASE").

IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange

IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2023 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Eyal Shamir - CEO Ronen Tsimerman - CFO & COO Todd Kehrli - EVC Group, IR Conference Call Participants Kemp Dolliver - Brookline Capital Markets Ben Haynor - Alliance Global Partners Chaitanya G. - H.C. Wainwright Operator Good morning, and thank you for standing by.

IceCure Medical Ltd (ICCM) Q4 2022 Earnings Call Transcript

Rising Utilization of ProSense in the U.S. Market Generates Year-over-Year Consumable Revenue Growth Physician Adoption Continues to Grow Ahead of the FDA's Response to the Company's Application for Marketing Approval in Breast Cancer Indication Regulatory Approval Received in China for Commercial Use of IceSense3 Disposable Cryoprobes, to be Used in Combination with its IceSense3 Cryoablation System Console, Which was Previously Approved in China Cryoablation System and Cryoprobes to be Sold in China Through Exclusive Distribution Partnership Conference Call to be Held Today at 10:00 am Eastern Time CAESAREA, Israel , March 29, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense System of minimally-invasive cryoablation technology that destroys tumors by freezing, today reported audited financial results as of and for the twelve months ended December 31, 2022.

IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023

This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approved by the NMPA Products to be distributed in China through agreement with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co. Ltd.

IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes

CAESAREA, Israel , March 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, announced that it will release its full year financial and operational results for the twelve months ended December 31, 2022, prior to the market open on Wednesday, March 29, 2023,  and will host a conference call at 10:00 a.m.

IceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023

Jerash holdings (US) Inc

MamaMancini's Holdings

Onfolio Holdings Inc

One Stop Systems

Research Solutions

Stran & Company Inc

While some financial advisors may recommend a small portion of their clients' portfolios to be directed toward higher-risk ventures, hardly any will suggest speculative penny stocks. Suffering from technical issues such as low volume and extremely high volatility, this segment of the capital markets won't be for everyone.

7 Speculative Penny Stocks to Bet On This March

- Significant regulatory and reimbursement milestones achieved - Positive interim clinical results for ProSense in the treatment of kidney tumors and breast cancer - Fortified balance sheet with $23.6 million in cash and cash equivalents including short-term deposits as of December 31, 2022 - ProSense System and disposable cryoprobe sales continue to increase in the U.S. CAESAREA, Israel , Feb. 9, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced preliminary unaudited year-end financial results for the twelve months ended December 31, 2022.

IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights

Panel discussion included doctors currently using the ProSense cryoablation system Live ProSense demonstrations conducted at IceCure's booth CAESAREA, Israel , Jan. 26, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced its participation in the Society of Interventional Oncology's Annual Scientific Meeting ("SIO2023") in Washington, D.C.

IceCure's ProSense Featured in Breast Session at the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C.

Professional training courses are well-timed following IceCure's FDA filing for marketing authorization of ProSense with breakthrough indication CAESAREA, Israel , Jan. 25, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced that on January 13-14, 2023, the Company participated in the American Society of Breast Surgeons ("ASBrS") Breast Fellows Ultrasound Course in Cincinnati, Ohio.

IceCure's ProSense Presented in Hands-On Training Course at The American Society of Breast Surgeons Breast Follows Ultrasound Course

Patent has also been granted or allowed in major markets, including the European Union and Japan Cryogenic pump potentially broadens clinical indications for IceCure's cryoablation platform technology CAESAREA, Israel , Jan. 23, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "Cryogen Pump".

U.S. Patent Office Grants Notice of Allowance to IceCure for Novel Cryogenic Pump for Next-Generation Cryoablation Systems

Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowed Cryogenic pump enables multiple and longer duration procedures without the need to refill liquid nitrogen, potentially expanding clinical indications CAESAREA, Israel , Jan. 18, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it has received a Notice of Allowance from the Japan Patent Office (the "JPO") for IceCure's patent application titled "Cryogen Pump".

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems

Medtronic

CAESAREA, Israel , Jan. 4, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.

IceCure Medical CEO Issues Letter to Shareholders

CAESAREA, Israel , Dec. 23, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the closing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the "Ordinary Shares") priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share.

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CAESAREA, Israel , Dec. 21, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the pricing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the "Ordinary Shares") priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share.

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Athenex

Avaya Holdings

Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Identifying Penny Stocks With High Potential

CAESAREA, Israel , Dec. 20, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares.

News for Icecure Medical Ltd Stock (ICCM)